Initiating Rare Disease Drug Discovery Projects

NEW YORK, Sept. 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Initiating Rare Disease Drug Discovery Projects

http://www.reportlinker.com/p0968583/Initiating-Rare-Disease-Drug-Discovery-Projects.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

In comparison with major diseases, the targeting of rare diseases poses many different challenges, necessitating consideration of bespoke R&D strategies for drug discovery efforts to be successful. This report examines the issues that need to be considered in the earliest stages of embarking on a rare disease project.Understand why rare diseases make attractive targets for launching new drug discovery projects.Identify the key challenges that are presented by low patient prevalences.Assess how the research strategy chosen can be influenced by the disease prevalence.Understand the importance of considering issues of similarity versus other orphan drugs.Compare the scenarios in which repurposing existing drugs offers advantages over the development of novel drugs, and vice versa.While disease prevalence has an impact on the commercial viability of a new treatment, returns are achievable even for ultra rare conditions. Rare diseases can provide sufficient opportunities for commercialization of multiple therapeutic agents. This is the case even for some ultra rare conditions such as Gaucher disease and Fabry disease.Both clinical experts and patient groups provide valuable resources in understanding a rare disease and in identifying potential patients for clinical studies.Many opportunities remain to develop treatments for untreated rare diseases. However, ultra rare diseases with high infant mortality present major challenges.Can more than one drug be a commercial success for treating rare indications?What are the best ways of identifying patients for recruitment into clinical trials?Why it is necessary to consider logistic issues in planning clinical studies?What are the requirements for a clinical candidate to treat a rare disease?What factors determine whether a small-molecule or biologic strategy is most suitable?

 

About the author

•Disclaimer

EXECUTIVE SUMMARY

•Choosing rare diseases to target

•Preclinical development

Introduction

•Key points regarding rare disease drug discovery

Choosing rare diseases to target

•Summary

•Introduction

•Key issues

•Commercial potential

- Prevalence

- Geographic distribution

- Disease understanding

- Available experts

- Current treatments

- What is similar?

•Conclusion

Preclinical development

•Summary

•Introduction

•Screen or repurpose?

- Repurposed

- Directed approaches

- Taking advantage of orphan drug status

•Other issues

- Small molecule or biological?

- Biological test models

- Requirements of a clinical candidate

•Conclusions

Appendix

•Scope

•Methodology

•Glossary/abbreviations

•Bibliography/references

 

FIGURES

•Figure: Schematic relationship between rare disease prevalence and commercial returns

•Figure: Identifying suitable patients for clinical studies

•Figure: The influence of prevalence on research strategy

•Figure: Current exploitation of rare disease space

•Figure: "Similar" approved BCR-ABL inhibitors with orphan drug status

•Figure: Similar approved endothelin receptor antagonists with orphan drug status

•Figure: Selecting a rare disease to target

•Figure: Alternative strategies to identifying new treatments for rare diseases

•Figure: Strategic pathways for identifying development candidates

 

Companies Mentioned

Amlin plc, Diageo plc, GlaxoSmithKline Plc, Hutchison 3G UK Limited, Informa plc, Sanofi, WPP Group plc

 

To order this report:

Drug_Discovery_and_Development Industry: Initiating Rare Disease Drug Discovery Projects

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.